Fagiolino P, Vázquez M, Savio E, Domínguez L, Aiache J M, Beyssac E
Department of Pharmacology and Biopharmacy, Faculty of Chemistry, Montevideo, Uruguay.
Eur J Drug Metab Pharmacokinet. 1998 Apr-Jun;23(2):160-5. doi: 10.1007/BF03189333.
In order to assess the extent and the rate of absorption in bioavailability studies, area under the curve (AUC), experimental maximum concentration (Cmax) and experimental time to reach Cmax (Tmax), are used. But when slow-release formulations are considered, the drug concentration-time curves usually show multiple peaks, and it is difficult to compute a Cmax and Tmax value. In case a Cmax value is computed, important variability in this parameter results in high values in the residual variance of the ANOVA test. So in order to decrease the high variability, average parameters: average concentration (Cav), average maximum concentration (Cmax,av) and Cmax,av x 100/Cav (%Cmax,av), are proposed. These new parameters were applied in a bioavailability study of slow-release amitriptyline formulation.
为了评估生物利用度研究中的吸收程度和吸收速率,采用了曲线下面积(AUC)、实验最大浓度(Cmax)和达到Cmax的实验时间(Tmax)。但是,当考虑缓释制剂时,药物浓度-时间曲线通常会出现多个峰值,难以计算Cmax和Tmax值。如果计算Cmax值,该参数的重要变异性会导致方差分析(ANOVA)测试的残差方差值偏高。因此,为了降低高变异性,提出了平均参数:平均浓度(Cav)、平均最大浓度(Cmax,av)和Cmax,av×100/Cav(%Cmax,av)。这些新参数应用于缓释阿米替林制剂的生物利用度研究。